Tags : Alliance

Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration

Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D […]Read More

Lilly and Innovent Report the Global Expansion of their Alliance

Shots: Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies will retain the right to study Tyvyt in combination with other therapies as part of their own clinical programs Lilly will get an exclusive license for the therapy for geographies […]Read More

Gates Foundation Forms an Alliance with Global Pharma Companies to

Shots: GSK, Evotec, J&J, Otsuka, the Bill & Melinda Gates Medical Research Institute and its foundation have launched the ‘PAN-TB collaboration’ project to collaboratively accelerate the development of novel TB treatment regimens The global collaboration will focus on developing a new regimen with the drug candidates that demonstrated efficacy in its P-II studies with limited […]Read More

Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full

Shots: The global companies modernize their alliance as of Jan 01, 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D, HF and CKD   As per the amended agreement, the companies will revise the margin sharing structure for ongoing payments from Jan 01, 2020. Trajenta (linagliptin) […]Read More

Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista

Shots: Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities In Jul’2019, Sanofi has terminated its 4yrs. […]Read More